Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE0006632003
Mon, 14.11.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, November 14, 2022   Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease  GRADUATE studies did not meet primary endpoint MorphoSys  [ … ]
Technical analysis Trade The News (TTN)
To the publication
Fri, 21.10.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, October 21, 2022 Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) Ant [ … ]
Technical analysis Trade The News (TTN)
To the publication
Fri, 21.10.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, October 21, 2022 Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) Ant [ … ]
Technical analysis Trade The News (TTN)
To the publication
Tue, 26.07.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, July 26, 2022   Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022   Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million [ … ]
Technical analysis Trade The News (TTN)
To the publication
Tue, 26.07.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, July 26, 2022   Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022   Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million [ … ]
Technical analysis Trade The News (TTN)
To the publication
Thu, 10.03.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 Planegg/Munich, Germany, March 10 2022 Ad hoc: MorphoSys AG reports non-cash impairment charge of approx. € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 20 [ … ]
Technical analysis Trade The News (TTN)
To the publication
Fri, 07.01.2022       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, January 07, 2022 Ad hoc: MorphoSys AG Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance   - Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million (€ 66.9 million) - Antici [ … ]
Technical analysis Trade The News (TTN)
To the publication
Mon, 26.07.2021       MorphoSys AG
DE0006632003

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 Planegg/Munich, Germany, July 26, 2021 Ad hoc: MorphoSys AG to update financial guidance for 2021 and reduce financial liabilities   MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces today an update of its financial guidance for 2021 after prelim [ … ]
Technical analysis Trade The News (TTN)
To the publication
Wed, 02.06.2021       MorphoSys AG
DE0006632003

Ad hoc release according to article 17 para. 1 MAR Planegg/Munich, Germany and Cambridge, Mass., June 2, 2021 Ad hoc: MorphoSys to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys"), announces today that it has entered into a definitive agreemen [ … ]
Technical analysis Trade The News (TTN)
To the publication
Tue, 27.10.2020       MorphoSys AG
DE0006632003

Ad hoc release according to article 17 para. 1 MAR Planegg/Munich, Germany, October 27, 2020 Ad hoc: MorphoSys AG Raises its Financial Guidance for the Full Year 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announces today an increase in its financial guidance for the financial year 2020 after preliminary c [ … ]
Technical analysis Trade The News (TTN)
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 05.07.2024, Calendar Week 27, 187th day of the year, 179 days remaining until EoY.